Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.
about
Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLCEarly Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.The role of PET/CT as a prognosticator and outcome predictor in lung cancer.Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot StudyRisk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235.Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"?Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation
P2860
Q33584618-D5090513-2B88-475C-BF77-06E4B6F7CA91Q36056706-D1E38E13-A804-4045-B09F-D4A5029DB20FQ36288418-7EFFE322-12AF-4E22-8E06-0E734285EF8AQ37180546-835E6C7C-0C14-4E9B-B623-78A58259081FQ38660859-72D69525-48C7-4977-9FB9-37BD46E13299Q38715401-E00A64AE-1B66-4513-B980-E7A6105D8F47Q38841400-556213A7-8862-46A6-96CF-E97D197A9317Q38925887-8E0CCD1F-3E5E-4C99-B913-56F67069BD5AQ39373649-CC8AEA24-D525-4609-854F-92A2A82BD6D8Q42363788-878FC88D-7755-4A86-A427-BB97CA1050DDQ47777467-0267159D-CEA0-42CE-B8FF-E9673634F725Q56764236-A23733D3-A6E0-4A68-AD71-1444D77F67E6
P2860
Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pretreatment FDG-PET metrics i ...... cancer: ACRIN 6668/RTOG 0235.
@ast
Pretreatment FDG-PET metrics i ...... cancer: ACRIN 6668/RTOG 0235.
@en
type
label
Pretreatment FDG-PET metrics i ...... cancer: ACRIN 6668/RTOG 0235.
@ast
Pretreatment FDG-PET metrics i ...... cancer: ACRIN 6668/RTOG 0235.
@en
prefLabel
Pretreatment FDG-PET metrics i ...... cancer: ACRIN 6668/RTOG 0235.
@ast
Pretreatment FDG-PET metrics i ...... cancer: ACRIN 6668/RTOG 0235.
@en
P2093
P2860
P356
P1476
Pretreatment FDG-PET metrics i ...... cancer: ACRIN 6668/RTOG 0235.
@en
P2093
Abass Alavi
Albert DeNittis
Barry A Siegel
Bradley S Snyder
Douglas W Johnson
Fenghai Duan
Jeffrey D Bradley
Jeremy J Gorelick
Nitin Ohri
P2860
P356
10.1093/JNCI/DJV004
P407
P577
2015-02-16T00:00:00Z